• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Canada·Healthcare·RX.V
Share

BioSyent Inc. Stocks

CA$ 14Last Updated 11.06.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

CA$ 113.87M

CA$ 14
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

BioSyent Inc. is a specialized pharmaceutical enterprise operating both within Canada and internationally. The company is actively involved in identifying, obtaining, developing, and commercializing a diverse portfolio of pharmaceutical and health-related products. Among its offerings are iron supplements such as FeraMAX 150, FeraMAX Powder (a water-soluble oral iron solution promoting red blood cell formation), and FeraMAX Pd Therapeutic 150, all designed to prevent and manage iron deficiency anemia. BioSyent also provides Cathejell, utilized for surface anesthesia and lubrication during various medical procedures including cystoscopy, catheterization, endoscopy, and tracheal intubation, as well as for symptomatic relief of pain associated with cystitis and urethritis. Other key products include RepaGyn, a vaginal suppository aimed at healing vaginal mucosa and alleviating dryness caused by factors like menopause, stress, and chemotherapy, and Proktis-M, a rectal suppository supporting the healing of the anal and rectal areas. Furthermore, its lineup features Combogesic for reducing moderate acute pain and fever in adults, Protect-It, a non-chemical, food-safe grain insecticide used to prevent insect infestations in stored grains, and Tibella, a hormone replacement therapy addressing vasomotor symptoms stemming from estrogen deficiency. The company distributes its products through wholesalers and retail pharmacy chains. Headquartered in Mississauga, Canada, BioSyent Inc. was incorporated in 2006, having previously operated as Hedley Technologies Inc. before rebranding in June 2006 to emphasize its strategic focus on the pharmaceutical sector.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of RX.V is 18 and suggests 29% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.06.2026 22:46

Trump canceled planned new strikes on Iran. Oil below $90 per barrel

11.06.2026 22:30

Wall Street assessed the potential of SpaceX stock: optimists expect a 40% increase from the IPO price

11.06.2026 21:39

Bezos' AI startup has increased its valuation to $41 billion, what do we know about it?

11.06.2026 20:51

Retail investors are willing to buy back more than $70 billion worth of SpaceX stock - Bloomberg

11.06.2026 20:19

Emirates has come up with a way to bring tourists back to Dubai. What does it offer?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026